News
-
-
PRESS RELEASE
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma achieves IRB approval for Phase I clinical trial of fast-acting high-dose aspirin formulation, targeting rapid drug delivery and enhanced bioavailability for suspected acute myocardial infarction treatment -
-
-
-
-
-
-
PRESS RELEASE
Avant Technologies and Ainnova Request Pre-Submission Meeting with US FDA for VisionAI Platform Technology
Ainnova and Avant plan FDA pre-submission meeting for VisionAI platform aimed at early disease detection using AI. Focus on FDA clearance for diabetic retinopathy detection technology -